Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03136055
Recruitment Status : Active, not recruiting
First Posted : May 2, 2017
Last Update Posted : October 9, 2020
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of California, San Francisco

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : July 1, 2023